BDR 331
Alternative Names: BDR-331Latest Information Update: 30 Jun 2022
Price :
$50 *
At a glance
- Originator MDimune
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 23 Jun 2022 BDR 331 is available for licensing as of 23 Jun 2022 (MDimune website, June 2022)
- 22 Jun 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before June 2022 (MDimune website, June 2022)
- 22 Jun 2022 Preclinical trials in Unspecified in South Africa (unspecified route) before June 2022 (MDimune website, June 2022)